Effect of olanzapine on scopolamine induced deficits in differential reinforcement of low rate 72 s (DRL-72 s) schedule in rats: Involvement of the serotonergic receptors in restoring the deficits

European Journal of Pharmacology

Volumn 720, Issue 1-3, 2013, Pages 344-354

  Jayarajan, Pradeep ^a,b   Nirogi, Ramakrishna ^a   Shinde, Anil ^a  

^a SUVEN LIFE SCIENCES LTD   (India)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

Donepezil; DRL 72 s; Haloperidol; Impulsivity; Olanzapine; SB 742457; Scopolamine

Indexed keywords

3 PHENYLSULFONYL 8 (1 PIPERAZINYL)QUINOLINE; DONEPEZIL; HALOPERIDOL; OLANZAPINE; SCOPOLAMINE; SEROTONIN 2A RECEPTOR; SEROTONIN 6 RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IMPULSIVENESS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; TASK PERFORMANCE;

DONEPEZIL; DRL-72S; HALOPERIDOL; IMPULSIVITY; OLANZAPINE; SB-742457; SCOPOLAMINE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CHOLINESTERASE INHIBITORS; CONDITIONING, OPERANT; HALOPERIDOL; IMPULSIVE BEHAVIOR; INDANS; MALE; MUSCARINIC ANTAGONISTS; PIPERIDINES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; REINFORCEMENT (PSYCHOLOGY); SCOPOLAMINE HYDROBROMIDE; SEROTONIN ANTAGONISTS; SULFONES;

EID: 84890128944     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.10.005     Document Type: Article

References (66)

1. E. Arce, and C. Santisteban Impulsivity: a review Psicothema 18 2 2006 213 220 (Pubitemid 44681963)
2. S. Barak, and I. Weiner Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs Int. J. Neuropsychopharmacol 12 2009 227 241
3. S. Barak, and I. Weiner Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine Psychopharmacology 209 2010 175 184
4. S. Barak, and I. Weiner Scopolamine induces disruption of latent inhibition, which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor Neuropsychopharmacology 32 2007 989 999 (Pubitemid 46631975)
5. C. Bolden, B. Cusack, and E. Richelson Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells J. Pharmacol. Exp. Ther. 260 1992 576 580
6. M. Cachard-Chastel, S. Devers, S. Sicsic, M. Langlois, F. Lezoualc'h, A.M. Gardier, and C. Belzung Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice Behav. Brain Res. 187 2008 455 461
7. A.T.T. Chuang, A. Foley, P,L. Pugh, D. Sunter, X. Tong, C. Regan, and L,A. Dawson 5-HT6 receptor antagonist SB-742457 as a novel cognitive enhancing agent for Alzheimer's disease Alzheimer Dementia 2 2006 S631 S632
8. A. Correa, M. Triviño, C. Pérez-Dueñas, A. Acosta, and J. Lupiáñez Temporal preparation, response inhibition and impulsivity Brain Cogn. 73 2010 222 228
9. J.M. Crook, E. Tomaskovic-Crook, D.L. Copolov, and B. Dean Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment Am. J. Psychiatry 158 2001 918 925 (Pubitemid 32547622)
10. V. Da Silva Costa-Aze, A. Quiedeville, M. Boulouard, and F. Dauphin 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice Psychopharmacology 222 2012 99 115
11. J.M. Davis, and N. Chen The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials J. Clin. Psychiatry 62 2001 757 771 (Pubitemid 33104662)
12. N.M. De Bruin, J. Prickaerts, A. van Loevezijn, J. Venhorst, L. de Groote, P. Houba, and O. Reneerkens Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats Neurobiol. Learn. Mem. 96 2011 392 402
13. B. Dean, J.M. Crook, K. Opeskin, C. Hill, N. Keks, and DL. Copolov The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia Mol. Psychiatry. 1 1996 54 58 (Pubitemid 126442395)
14. J,L. Evenden Varieties of impulsivity Psychopharmacology 146 4 1999 348 361 (Pubitemid 29513276)
15. J.J. Feigenbaum, B.H. Moon, R. Catterton, J. Yanai, and H.L. Klawans Haloperidol-induced plasma prolactin release: sensitivity, reliability, and comparison to haloperidol antagonism of dopamine agonist-induced stereotyped behavior in the rat Psychopharmacology 78 1982 383 384 (Pubitemid 13218581)
16. P.J. Fletcher Effects of combined or separate 5,7-dihydroxytryptamine lesions of the dorsal and median raphe nuclei on responding maintained by a DRL 20 s schedule of food reinforcement Brain Res. 675 1995 45 54
17. P.J Fletcher, M. Tampakeras, J. Sinyard, and G.A. Higgins Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test Psychopharmacology 195 2 2007 223 234 (Pubitemid 350045843)
18. O. Freudenreich, L. Herz, T. Deckersbach, A.E. Evins, D.C. Henderson, C. Cather, and D.C. Goff Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial Psychopharmacology 181 2 2005 358 363 (Pubitemid 41492206)
19. J.I Friedman, D.N. Adler, E. Howanitz, P.D. Harvey, G. Brenner, H. Temporini, L. White, M. Parrella, and K.L. Davis A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia Biol. Psychiatry 51 2002 349 357 (Pubitemid 34251171)
20. A. Gasbarri, I.B. Introini-Collison, M.G. Packard, C. Pacitti, and J.L. McGaugh Interaction of cholinergic-dopaminergic systems in the regulation of memory storage in aversively motivated learning tasks Brain Res. 627 1993 72 78 (Pubitemid 23309601)
21. G.A Higgins, L. Silenieks, W. Lau, S. Thevarkunnel, A. Henderson, and N. Moore Characterization of the 5-HT6 receptor antagonist, SB-742457, on cognitive test performance in the rat Soc. Neurosci. Meet. Abstr. 168 2010 18
22. D.B Hodges Jr., M.D. Lindner, J.B. Hogan, K.M. Jones, and E.J. Markus Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity Behav. Pharmacol. 20 2009 237 251
23. J.R. Homberg Serotonin and decision making processes Neurosci. Biobehav. Rev. 36 2012 218 236
24. I. Iancu, E. Bodner, S. Roitman, A. Piccone Sapir, A. Poreh, and M. Kotler Impulsivity, aggression and suicide risk among male schizophrenia patients Psychopathology 43 2010 223 229
25. C.K Jones, E.L Eberle, D.B Shaw, D.L McKinzie, and H.E. Shannon Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats J. Pharmacol. Exp. Ther. 312 2005 1055 1063 (Pubitemid 40293764)
26. A. Kaladjian, R. Jeanningros, J.M. Azorin, J.L. Anton, and P. Mazzola-Pomietto Impulsivity and neural correlates of response inhibition in schizophrenia Psychol. Med. 41 2011 291 299
27. R.S Keefe, R.M Bilder, S.M Davis, P.D Harvey, B.W Palmer, J.M Gold, and H.Y Meltzer Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial Arch. Gen. Psychiatry 64 2007 633 647 (Pubitemid 46878665)
28. J.E. Kelsey, and S.P. Grossman Influence of central cholinergic pathways on performance on free-operant avoidance and DRL schedules Pharmacol. Biochem. Behav. 3 1975 1043 1050
29. I. Klinkenberg, and A. Blokland The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies Neurosci. Biobehav. Rev. 34 2010 1307 1350
30. Y. Koyama, and Y. Kayama Mutual interactions among cholinergic, noradrenergic and serotonergic neurons studied by ionophoresis of these transmitters in rat brainstem nuclei Neuroscience 55 1993 1117 1126 (Pubitemid 23231921)
31. M.D Lindner, J.B Hogan, D.B Hodges Jr, A.F Orie, P. Chen, J.A. Corsa, and J.E. Leet Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping Psychopharmacology 188 2006 629 640 (Pubitemid 46758973)
32. G.J. Marek, A.A. Li, and L.S. Seiden Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential reinforcement-of-low-rate 72-s schedule J. Pharmacol. Exp. Ther. 250 1989 52 59 (Pubitemid 19194973)
33. G.J. Marek, A.A. Li, and L.S. Seiden Evidence for involvementof 5-hydroxytryptamine1 receptors in antidepressant-like 5-HT Mediation of DRL 72 s J. Pharmacol. Exp. Ther. 250 1989 60 71
34. D. Mazeh, H. Zemishlani, Y. Barak, I. Mirecki, and D. Paleacu Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study Int. Psychogeriatr. 18 3 2006 429 436 (Pubitemid 44128317)
35. J. McGaughy, J. Turchi, and M. Sarter Crossmodal divided attention in rats: effects of chlordiazepoxide and scopolamine Psychopharmacology 115 1994 213 220 (Pubitemid 24207784)
36. E.S. Mitchell, and J.F. Neumaier 5-HT6 receptors: a novel target for cognitive enhancement Pharmacol. Ther. 108 2005 320 333 (Pubitemid 41691871)
37. J. Monahan, H.J. Steadman, P.S. Appelbaum, P.C. Robbins, E.P. Mulvey, and E. Silver Developing a clinically useful actuarial tool for assessing violence risk Br. J. Psychiatry 176 2000 312 319
38. J.M. O'Donnell, and L.S. Seiden Differential-reinforcement-of-low-rate 72-s schedule: selective effects of antidepressant drugs J. Pharmacol. Exp. Ther. 224 1983 80 88 (Pubitemid 13171034)
39. J.M. O'Donnell, G.J. Marek, and L.S. Seiden Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low- rate (DRL) operant schedule Neurosci. Biobehav. Rev. 29 2005 785 798 (Pubitemid 40755464)
40. E.K Perry, and R.H. Perry Acetylcholine and hallucinations, disease-related compared to drug-induced alterations in human consciousness Brain Cogn. 28 1995 240 258
41. P.J Perry, D.C Wilding, and R.P. Juhl Anticholinergic psychosis Am. J. Hosp. Pharm. 35 1978 725 728
42. M.R. Picciotto, MJ. Higley, and Y.S. Mineur Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior Neuron 76 2012 116 129
43. T.J. Raedler, and R. Tandon Cholinergic mechanisms in schizophrenia: current concepts Curr. Psychosis Ther. Rep. 4 2006 20 26 (Pubitemid 44623834)
44. T.J. Raedler, M.B. Knable, D.W. Jones, R.A. Urbina, JG. Gorey, K.S. Lee, and M.F. Egan In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia Am. J. Psychiatry 160 2003 118 127 (Pubitemid 36042435)
45. T.J. Raedler, F.P. Bymaster, R. Tandon, D Copolov, and B. Dean Towards a muscarinic hypothesis of schizophrenia Mol. Psychiatry. 12 2007 232 246 (Pubitemid 46328501)
46. J.B. Richards, K.E. Sabol, and L.S. Seiden DRL interresponse-time distributions: quantification by peak deviation analysis J. Exp. Anal. Behav. 60 1993 361 385
47. T.W. Robbins, and S.D. Iversen Amphetamine induced disruption of temporal discrimination by response disinhibition Nat.: New Biol. 245 1973 191 192
48. B.L Roth, S.C. Craigo, M.S. Choudhary, A. Uluer, F.J Monsma Jr., Y. Shen, and H.Y. Meltzer Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors J. Pharmacol. Exp. Ther. 268 1994 1403 1410 (Pubitemid 24100360)
49. B.L Roth, S.M Hanizavareh, and A.E Blum Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders Psychopharmacology 174 2004 17 24 (Pubitemid 38925086)
50. S. Ruotsalainen, R. Miettinen, E. MacDonald, E. Koivisto, and J. Sirviö Blockade of muscarinic, rather than nicotinic, receptors impairs attention, but does not interact with serotonin depletion Psychopharmacology 148 2000 111 123 (Pubitemid 30104132)
51. A. Sambeth, W.J. Riedel, L.T. Smits, and A. Blokland Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG? Eur. J. Pharmacol. 572 2007 151 159 (Pubitemid 47429642)
52. E. Scarr, and B. Dean Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia? J. Neurochem. 107 2008 1188 1195
53. S. Schlegel, R. Schlösser, C. Hiemke, O. Nickel, A. Bockisch, and K. Hahn Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT Psychopharmacology 124 1996 285 287
54. P. Singer, and B.K. Yee Reversal of scopolamine-induced disruption of prepulse inhibition by clozapine in mice Pharmacol. Biochem. Behav. 101 1 2012 107 114
55. P.J. Snyder, M.M. Bednar, J.R. Cromer, and P. Maruff Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor Alzheimer Dementia 1 2005 126 135 (Pubitemid 43348841)
56. B. Spivak, E. Shabash, B. Sheitman, A. Weizman, and R. Mester The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study J. Clin. Psychiatry. 64 2003 755 760 (Pubitemid 36897210)
57. T. Steckler, and A. Sahgal Psychopharmacological studies in rats responding at touch-sensitive devices Psychopharmacology 118 1995 226 229
58. R.D Strous, M. Kupchik, S. Roitman, S. Schwartz, N. Gonen, R. Mester, and A. Weizman Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study Hum. Psychopharmacol. 21 2006 235 243 (Pubitemid 44043767)
59. J.C Talpos, L.S Wilkinson, and T.W. Robbins A comparison of multiple 5-HT receptors in two tasks measuring impulsivity J. Psychopharmacol. 20 1 2006 47 58
60. A.V Terry Jr. Role of the central cholinergic system in the therapeutics of schizophrenia Curr. Neuropharmacol. 6 2008 286 292
61. N. Tual, KM. Yazc, AE. Yacolu, and A. Gogus A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia Int. J. Neuropsychopharmacol. 7 2004 117 123 (Pubitemid 38823278)
62. C.A Winstanley, Y. Chudasama, J.W. Dalley, D.E. Theobald, J.C. Glennon, and T.W. Robbins Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats Psychopharmacology 167 3 2003 304 314 (Pubitemid 36712978)
63. 6) receptors in vivo Eur. J. Pharmacol. 15 2012 6 11
64. M.C. Zanarini, and F.R. Frankenburg Olanzapine treatment of female borderline personality disorder patients: a doubleblind, placebo-controlled pilot study J. Clin. Psychiatry 62 2001 849 854 (Pubitemid 33131170)
65. K. Zavitsanou, A. Katsifis, Y. Yu, and X.F. Huang M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders Brain Res. Bull. 65 2005 397 403
66. W. Zhang, and F.P. Bymaster The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D-1, D-2, D-3, 5HT (2A) and muscarinic receptors Psychopharmacology 141 1999 267 278 (Pubitemid 29196076)